Amphastar Pharmaceuticals Inc.'s longtime legal head has left the company as part of an effort to simplify management by “removing a layer” from its organizational structure.
Jason Shandell, general counsel since December 2008 and president of Amphastar since June 2013, resigned April 10 from both roles, as well as his position as a member of the specialty pharmaceutical company’s board of directors, according to a Monday press release and securities filing by Amphastar.
Shandell will receive nearly $2.43 million in cash severance and Amphastar has agreed to vest 80% of its unvested stock options and restricted stock units, the generic ...